Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.

Endocrine · 2024 · PMC11291544 · PMID 38448675

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

While an increased susceptibility to COVID-19 was noted, dapagliflozin showed a trend in reducing the risk of progressing to severe COVID-19, although this trend did not reach statistical significance [ 55 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.